Clinical Evidence Grows in Support of CyberKnife Treatment for Intracranial and Extracran...( SUNNYVALE Calif. Feb. 26 /- Accur...),Health

SUNNYVALE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced highlights from the clinical and technical presentations from its 8th Annual CyberKnife Users' Meeting, which was held February 4-7, 2009, in Hollywood, Fla. The record number of presentations featured during the event is a testament to the growing interest in use of the CyberKnife(R) Robotic Radiosurgery System for the non-invasive treatment of tumors anywhere in the body.

This year's CyberKnife Users' Meeting attracted more than 500 attendees, including surgeons, radiation oncologists, medical physicists, hospital administrators and other related clinical staff. More than 15 percent of those in attendance traveled from outside of the United States to participate. This year's scientific program grew noticeably from last year's with more than 85 oral presentations and 75 clinical and technical posters. The treatment of extracranial tumors was the focus of 47 of the oral presentations.

At this year's meeting, nine presentations reported on large-scale studies, each with more than 100 patients with brain, lung or prostate tumors. The 2009 Users' Meeting included 11 presentations related to prostate cancer treatment, with follow-up data approaching three years for many patients. In addition to updated outcomes with longer follow-up, researchers are extending CyberKnife applications for prostate cancer beyond early-stage disease. For example, clinicians discussed their use of CyberKnife radiosurgery to "boost" the radiation dose after conventional radiation therapy for patients with advanced disease, as well as for the treatment of recurrent cancer in patients that failed conventional radiation therapy.

The adoption of CyberKnife radiosurgery for th
'/>"/>